Rafael Ponce Email

EVP, Preclinical Development . Shape Therapeutics

Current Roles

Employees:
178
Revenue:
$34.5M
About
Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy. Our novel technology platform enables direct in vivo targeting/modification of RNA by leveraging ADARs (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and immune-stealth adeno-associated viruses (AAVs). ShapeTx is providing solutions to many of the challenges that contemporary genome engineering technologies face (like CRISPR, TALENs, etc.), such as permanent off-target damage, high risk of immunogenicity and therefore low in vivo applicability as effective gene therapy approaches. ShapeTxᅢᄁ¬ツᆲ¬トᄁs technology instead engages natural human cellular machinery to target RNA with high in vivo efficiency. Shape Genome, Shape Life!
Shape Therapeutics Address
219 Terry Ave N
Seattle, WA
United States
Shape Therapeutics Email

Past Companies

Shape Therapeutics, Inc.EVP, Preclinical Development
Juno Therapeutics, Inc.Sr. Director, Preclinical Sciences
AmgenScientific Director

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.